PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 1, 2015, Pages 682-689

  Li, Jingwu ^a,b   Cui, Jianzhong ^a   Zhang, Jinghua ^b   Liu, Yuanting ^b   Han, Longcai ^b   Jia, Chunliang ^b   Deng, Jingyu ^c   Liang, Han ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b TANGSHAN PEOPLE S HOSPITAL   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Lymph node; Neoplasm; Protein inhibitor of activated signal transducer and activators of transcription 3; Stomach; Survival

Indexed keywords

MESSENGER RNA; PROTEIN INHIBITOR OF ACTIVATED STAT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STOMACH CANCER;

EID: 84922985858     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27-39.
2. Schmidt B, Yoon SS. Varying Lymphadenectomies for Gastric Adenocarcinoma in the East Compared with the West: Effect on Outcomes. Am Soc Clin Oncol Educ Book 2012; 32: 250-255.
3. Li Y, Yang Y, Lu M, and Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterolog 2011; 58: 2166-2170.
4. Groner B. Determinants of the extent and duration of STAT3 signaling. JAK-STAT 2012; 1: 3, 211-215.
5. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
6. Deng J, Liang H, Zhang R, Sun D, Pan Y, Liu Y, Zhang L, Hao X. STAT3 is associated with lymph node metastasis in gastric cancer. Tumour Biol 2013; 34: 2791-2800.
7. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2000; 278: 9-13.
8. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol 1994; 10: 12-20.
9. Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R. Lymphadenectomy in gastric adenocarcinoma: a prospective and prognostic study. Arch Surg 1992; 127: 290-294.
10. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat 3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003; 9: 594-600.
11. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 2005; 5: 593-605.
12. Rosas-Acosta G, Langereis MA, Deyrieux A and Wilson VG. Proteins of the PIAS family enhance the sumoylation of the papillomavirus E1 protein. Virology 2005; 331: 190-203.
13. Jackson PK. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 2001; 15: 3053-3058.
14. Castillo-Lluva S, Tatham MH, Jones RC, Jaffray EG, Edmondson RD, Hay RT, Malliri A. SUMOylation of the GTPase Rac1 is required for optimal cell migration. Nat Cell Biol 2010; 12: 1078-1085.
15. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998; 95: 10626-10631.
16. Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004; 11: 1319-1324.
17. Liu LM, Yan MG, Yang DH, Sun WW, Zhang JX. PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues. Clin Res Hepatol Gastroenterol 2011; 35: 393-398.